Author
Listed:
- Kieran L. Quinn
(University of Toronto
Sunnybrook Health Sciences Centre)
- Erin M. Macdonald
(Institute for Clinical Evaluative Sciences)
- Tara Gomes
(Institute for Clinical Evaluative Sciences
University of Toronto
St. Michael’s Hospital)
- Muhammad M. Mamdani
(Institute for Clinical Evaluative Sciences
University of Toronto
St. Michael’s Hospital
King Saud University)
- Anjie Huang
(Institute for Clinical Evaluative Sciences)
- David N. Juurlink
(Institute for Clinical Evaluative Sciences
University of Toronto
St. Michael’s Hospital
Sunnybrook Health Sciences Centre)
Abstract
Introduction Digoxin is commonly prescribed to elderly patients with heart failure and atrial fibrillation, and macrolide antibiotics markedly increase the risk of digoxin toxicity. Objective The aim was to determine whether, in older patients receiving digoxin, macrolide antibiotics are associated with sudden death. Methods We used a population-based, nested, case–control design from January 1, 1994 to December 31, 2012 in a cohort of Ontario residents aged 66 years or older prescribed digoxin. The primary outcome was the risk of sudden death within 14 days of exposure to one of three antibiotics (erythromycin, clarithromycin, or azithromycin), relative to cefuroxime. Results Among 39,072 Ontarians who died suddenly while receiving digoxin, 586 died within 14 days of receiving a study antibiotic. Relative to cefuroxime, we found no statistically significant increase in the risk of sudden death following treatment with erythromycin [adjusted odds ratio (aOR) 0.98; 95% confidence interval (CI) 0.65–1.48], clarithromycin (aOR 1.25; 95% CI 0.94–1.65), or azithromycin (aOR 1.07; 95% CI 0.75–1.53). Conclusion This finding reinforces the cardiovascular safety of macrolide antibiotics in a high-risk population.
Suggested Citation
Kieran L. Quinn & Erin M. Macdonald & Tara Gomes & Muhammad M. Mamdani & Anjie Huang & David N. Juurlink, 2017.
"Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study,"
Drug Safety, Springer, vol. 40(9), pages 835-840, September.
Handle:
RePEc:spr:drugsa:v:40:y:2017:i:9:d:10.1007_s40264-017-0539-9
DOI: 10.1007/s40264-017-0539-9
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:40:y:2017:i:9:d:10.1007_s40264-017-0539-9. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.